Acino ? Delivering Health

More documents

Recommendations

Info

Promising potential areas of synergies through integration 2013 2014 Basle HQ and R&D activities will be moved to Aesch by end 2012 Mepha main warehouse activities transferred to <strong>Acino</strong> premises by January 2013 Combined technical operations structures New R&D structure (including regulatory) established Engineering (rollout internal engineering, reduction external services) Finance, HR and IT systems Cont. Potential synergies p.a. in EUR million Synchronisation of market intelligence 0.5 1.0 0.8 2.6 1.0 0.6 3.5 Total 10.0 84
Syndication financing terms Facility: - EUR 110 million Maturity: - 5 years - amortizing min. EUR 10 million p.a. starting 2013, remaining amount until 2017 Interest rate - EURIBOR + margin dependent to net debt / EBITDA ratio - All in cost : currently below 3% p.a. Employed per November 30, 2012: EUR 100 million Financial Summary: (in EUR millions) 2012 2013 2014 P&L charge (est.) 2.5 (*) 2.9 2.6 EPS impact (EUR) 0.74 0.85 0.77 (*) without one time charges 85
Page 1 and 2:
Acino - Delivering Health Investor
Page 3 and 4:
Acino - drug delivery specialist, m
Page 5 and 6:
Acino’s growth drivers Fully expl
Page 7 and 8:
Technology platform Oral modified r
Page 9 and 10:
Oral modified release forms MUPS (M
Page 11 and 12:
Technology platform Oral dispersibl
Page 13 and 14:
Technology platform Transdermal sys
Page 15 and 16:
Transdermal systems Why transdermal
Page 17 and 18:
Technology platform Extended releas
Page 19 and 20:
Extended release parenterals Advant
Page 21 and 22:
Development projects Ferrous sulfat
Page 23 and 24:
Development projects Rivastigmine T
Page 25 and 26:
Development projects Goserelin & le
Page 27 and 28:
Development projects Goserelin 1 &
Page 29 and 30:
Development projects Leuprorelin 1
Page 31 and 32:
Acino’s development pipeline Stat
Page 33 and 34: Acino - Delivering Health Thank you
Page 35 and 36: Entering emerging markets / “Swis
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 43 and 44: Opportunities Products with added v
Page 45 and 46: Acino Switzerland: Product Portfoli
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54: Optimized BtB Concept - Geographica
Page 55 and 56: Technical Marketing and Operations:
Page 57 and 58: Acino’s production importance Tec
Page 59 and 60: Production Technologies: Value for
Page 61 and 62: Pellets Innovative technologies for
Page 63 and 64: Pellet Projects High volume project
Page 65 and 66: Granulates Hot melt granulation Sp
Page 67 and 68: Manufacturing Process 67
Page 70 and 71: Implants Implant manufacturing capa
Page 72 and 73: Opportunity: High Quality Service S
Page 74 and 75: Summary Focus on niche technologies
Page 76 and 77: Competitive advantage factor: HighT
Page 78 and 79: Micro Error Tracking System (METS)
Page 80 and 81: Strategy to cope with declining mar
Page 82 and 83: Financials Robert Schmid, Head of I
Page 86 and 87: Reduced currency exposure Mepha / C
Page 88 and 89: Summary and strategy Peter Burema,
Page 90 and 91: Acino’s growth drivers Fully expl
Page 92 and 93: Geographic break-down of revenue DE
Page 94: Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?